Cargando…

Corrigendum to “Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs” [Clin. Mass Spectrom. 14(Part A) (2019) 34–45]

Detalles Bibliográficos
Autores principales:	Kuhlin, Johanna, Sturkenboom, Marieke G.G., Ghimire, Samiksha, Margineanu, Ioana, van den Elsen, Simone H.J., Simbar, Noviana, Akkerman, Onno W., Jongedijk, Erwin M., Koster, Remco A., Bruchfeld, Judith, Touw, Daan J., Alffenaar, Jan-Willem C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400071/ https://www.ncbi.nlm.nih.gov/pubmed/36035622 http://dx.doi.org/10.1016/j.jmsacl.2022.08.001

Ejemplares similares

Corrigendum to “Instability of 7-aminoclonazepam in frozen storage conditions” [Clin. Mass Spectrom. 9 (2018) 23–24]
por: Dahlin, Jayme L., et al.
Publicado: (2022)

Corrigendum to “Analytical validation of protein biomarkers for risk of spontaneous preterm birth” [Clin. Mass Spectrom. 3 (2017) 25–38]
por: Bradford, Chad, et al.
Publicado: (2022)

Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study
por: van den Elsen, Simone HJ, et al.
Publicado: (2020)

Dataset of target mass spectromic proteome profiling for human chromosome 18
por: Ilgisonis, Ekaterina V., et al.
Publicado: (2016)

Corrigendum to “Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease” [Clin. Mass Spectrom. 14 (Part B) (2019) 74–82]
por: Hansson, Karl, et al.
Publicado: (2022)

Corrigendum to “Observation of a positive interference in LC-MS/MS measurement of d6-25-OH-vitamin D3” [Clin. Mass Spectrom. 3 (2017) 22–24]
por: Fortuna, Danielle, et al.
Publicado: (2022)

Practices of therapeutic drug monitoring in tuberculosis: an international survey
por: Margineanu, Ioana, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Ganciclovir: Where Are We?
por: Märtson, Anne-Grete, et al.
Publicado: (2022)

TB therapeutic drug monitoring – analysis of opportunities in Romania and Ukraine
por: Margineanu, I., et al.
Publicado: (2023)

Relevance of the drug–drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat
por: Dekkers, Bart G.J., et al.
Publicado: (2019)

Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005–2015
por: Pradipta, Ivan S., et al.
Publicado: (2019)

Corrigendum to “Migration from RIA to LC-MS/MS for aldosterone determination: Implications for clinical practice and determination of plasma and urine reference range intervals in a cohort of healthy Belgian subjects” [Clin. Mass Spectrom. 9 (2018) 7–17]
por: Le Goff, Caroline M., et al.
Publicado: (2022)

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial
por: Espinosa-Pereiro, Juan, et al.
Publicado: (2022)

eHealth in TB clinical management
por: Margineanu, I., et al.
Publicado: (2022)

Treatment outcomes of patients with MDR-TB in Nepal on a current programmatic standardised regimen: retrospective single-centre study
por: Ghimire, Samiksha, et al.
Publicado: (2020)

Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment
por: Keutzer, Lina, et al.
Publicado: (2023)

In vitro evaluation of an intravenous microdialysis catheter for therapeutic drug monitoring of gentamicin and vancomycin
por: van der Mast, Jackelien E., et al.
Publicado: (2019)

Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis
por: Mockeliunas, Laurynas, et al.
Publicado: (2022)

A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva
por: Alffenaar, Jan-Willem C, et al.
Publicado: (2020)

1538. Who Will Benefit From Therapeutic Drug Monitoring of Ganciclovir?
por: Martson, Anne-Grete, et al.
Publicado: (2019)

Comment on: “Analysis of Silicones Released from Household Items and Baby Articles by Direct Analysis in Real Time-Mass Spectrometry” by Jürgen H. Gross. J. Am. Soc. Mass Spectrom. 26, 511–521 (2015)
por: Thomas, Karluss
Publicado: (2016)

Ganciclovir Therapeutic Drug Monitoring: A Case Series
por: Märtson, Anne-Grete, et al.
Publicado: (2019)

Therapeutic Drug Monitoring of Antimicrobial Drugs in Neonates: An Opinion Article
por: Touw, Daan J., et al.
Publicado: (2022)

Patients and Medical Staff Attitudes Toward the Future Inclusion of eHealth in Tuberculosis Management: Perspectives From Six Countries Evaluated using a Qualitative Framework
por: Margineanu, Ioana, et al.
Publicado: (2020)

Ganciclovir therapeutic drug monitoring in transplant recipients
por: Märtson, Anne-Grete, et al.
Publicado: (2021)

Short-term PsychoEducation for Carers To Reduce Over Medication of people with intellectual disabilities (SPECTROM): study protocol
por: Deb, Shoumitro, et al.
Publicado: (2020)

Short-Term Psycho-Education for Caregivers to Reduce Overmedication of People with Intellectual Disabilities (SPECTROM): Development and Field Testing
por: Deb, Shoumitro (Shoumi), et al.
Publicado: (2021)

Dried Blood Spot Sampling to Assess Rifampicin Exposure and Treatment Outcomes among Native and Non-Native Tuberculosis Patients in Paraguay: An Exploratory Study
por: Ghimire, Samiksha, et al.
Publicado: (2023)

Subtherapeutic Exposure of Ganciclovir in Children Despite Appropriate Dosing: A Short Communication
por: Marfil, Sjanene, et al.
Publicado: (2023)

Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs
por: Sturkenboom, Marieke G. G., et al.
Publicado: (2021)

Identification of newly developed advanced schistosomiasis with MALDI-TOF mass spectrometry and ClinProTools analysis
por: Huang, Yuzheng, et al.
Publicado: (2019)

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)

Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China
por: Zheng, Xubin, et al.
Publicado: (2022)

Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations
por: Märtson, Anne‐Grete, et al.
Publicado: (2019)

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study
por: Davies Forsman, Lina, et al.
Publicado: (2018)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
por: Maryandyshev, Andrey, et al.
Publicado: (2017)

Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania
por: Mohamed, Sagal, et al.
Publicado: (2021)

Mass drug administration for malaria
por: Poirot, Eugenie, et al.
Publicado: (2013)

Mass drug administration for malaria
por: Shah, Monica P, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Posaconazole: an Update
por: Dekkers, Bart G. J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5r8vrch1h4dnmrkp6qmoanvu54